Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
44 hedge funds and large institutions have $21.9M invested in Biolase, Inc. in 2013 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
19% more funds holding
Funds holding: 37 → 44 (+7)
47% less capital invested
Capital invested by funds: $41.2M → $21.9M (-$19.4M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $26K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$6.99M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$1.51M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$677K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$580K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$548K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$6.96M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$5.06M |
| 3 |
DCM
Dialectic Capital Management
Norwalk,
Connecticut
|
-$288K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$193K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$96.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
51
Meeder Asset Management
Dublin,
Ohio
| $2K | – | – | – |
|
52
Barclays
London,
United Kingdom
| $1K | – | – | – |
|
53
Citigroup
New York
| $1K | – | – | – |
|
54
Group One Trading
Chicago,
Illinois
| $1K | – | – | – |
|
|
LTFS
55
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
57
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | – | – | – |
|
|
DCM
58
Dialectic Capital Management
Norwalk,
Connecticut
| – | -$288K | -7 | Closed |
|
59
JP Morgan Chase
New York
| – | -$77K | -2 | Closed |
|
BIOL Hedge Fund Activity: Q3 2013 in Review
44 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q3 2013, worth a combined $21.9M — down 47% from $41.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BIOL positions and 3 closed out — a net gain of 7 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $6.99M. The largest seller was Eagle Asset Management, cutting an estimated $6.96M.
- 44 institutional investors held Biolase, Inc. (BIOL) as of Q3 2013, up from 37 in Q2 2013.
- Funds reported $21.9M of Biolase, Inc. stock for Q3 2013, down 47% quarter-over-quarter.
- 10 funds opened new Biolase, Inc. positions in Q3 2013 and 3 closed out, a net change of +7 holders.
- The largest Biolase, Inc. buyer in Q3 2013 was Camber Capital Management, an estimated $6.99M added.
- The largest Biolase, Inc. seller in Q3 2013 was Eagle Asset Management, an estimated $6.96M sold.
Based on aggregated 13F filings for Q3 2013.